Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GREGORY M GIESLER

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1477518454
CMS profile
339251
Location
PASADENA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,120.82

108 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,120.82 108

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GREGORY M GIESLER

NPI 1477518454 · CMS profile ID 339251

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

PASADENA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1477518454?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GREGORY M GIESLER, NPI 1477518454, CMS profile ID 339251. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1477518454?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). GREGORY M GIESLER, NPI 1477518454, CMS profile ID 339251. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1477518454?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
GREGORY M GIESLER, NPI 1477518454, CMS profile ID 339251, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1477518454?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

108 matching records · $2,120.82 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 108 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 108.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Abbott Laboratories $9.4707/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920473861 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $17.4007/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 876357171 CMS
E.R. Squibb & Sons, L.L.C. $19.4907/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932969387 CMS
Amgen Inc. $20.2007/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939209733 CMS
Novartis Pharmaceuticals Corporation $18.3407/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893697173 CMS
AstraZeneca Pharmaceuticals LP $16.8206/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915004297 CMS
Boston Scientific Corporation $20.8406/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916794863 CMS
Merck Sharp & Dohme LLC $19.4106/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944174267 CMS
Amgen Inc. $4.8606/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939209731 CMS
PFIZER INC. $22.3106/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949160513 CMS
PFIZER INC. $19.0906/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949174123 CMS
Novartis Pharmaceuticals Corporation $23.2006/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893697171 CMS
Amgen Inc. $18.0406/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939209723 CMS
Novartis Pharmaceuticals Corporation $10.5906/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893697167 CMS
AstraZeneca Pharmaceuticals LP $19.0806/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914813333 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.9806/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887609989 CMS
PFIZER INC. $20.6605/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949143877 CMS
E.R. Squibb & Sons, L.L.C. $22.6105/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932969293 CMS
Amgen Inc. $17.8005/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939209721 CMS
Boston Scientific Corporation $16.4205/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916794857 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $17.4605/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 876357173 CMS
E.R. Squibb & Sons, L.L.C. $18.8904/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932969277 CMS
Novartis Pharmaceuticals Corporation $15.9304/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893697163 CMS
Esperion Therapeutics, Inc. $23.2204/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947255797 CMS
Amgen Inc. $21.4104/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939209729 CMS
Abbott Laboratories $19.9404/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920504341 CMS
AstraZeneca Pharmaceuticals LP $16.7304/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914702641 CMS
Janssen Pharmaceuticals, Inc $23.9904/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885810917 CMS
PFIZER INC. $19.7804/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949127615 CMS
PFIZER INC. $20.6604/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949124383 CMS
Novartis Pharmaceuticals Corporation $21.2204/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893697159 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.6404/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887355829 CMS
Amgen Inc. $16.8003/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939209727 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.9303/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887609991 CMS
PFIZER INC. $22.1803/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949079705 CMS
Boston Scientific Corporation $17.9003/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916794859 CMS
Novartis Pharmaceuticals Corporation $18.1303/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893697151 CMS
Abbott Laboratories $10.4903/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914213173 CMS
AstraZeneca Pharmaceuticals LP $17.3003/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915737907 CMS
Edwards Lifesciences Corporation $36.8503/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943820779 CMS
LivaNova USA, Inc. $24.3903/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942199283 CMS
Amgen Inc. $4.3403/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939209725 CMS
Novartis Pharmaceuticals Corporation $17.3102/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893697155 CMS
E.R. Squibb & Sons, L.L.C. $23.1102/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932969319 CMS
PFIZER INC. $18.5702/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949073091 CMS
Novartis Pharmaceuticals Corporation $18.3802/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893697143 CMS
AstraZeneca Pharmaceuticals LP $19.1102/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914782147 CMS
PFIZER INC. $23.9502/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949062797 CMS
Abbott Laboratories $15.0901/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920478477 CMS
Amgen Inc. $16.2301/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939209719 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,131.48 122
PY2020 $937.28 54
PY2021 $1,581.60 81
PY2022 $2,120.82 108
PY2023 $2,036.64 92
PY2024 $3,160.11 134
PY2025 $2,425.17 95

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $359,051.88 116

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

116 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $554.88 12/19/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184279284
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,400.00 12/19/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184279286
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $180.24 12/19/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184279288
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $345.00 12/19/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184279290
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,058.64 12/11/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184274769
Principal investigator 1 Alnylam Pharmaceuticals Inc. $800.00 12/01/2025 Non-covered Recipient Entity
Southern California Heart Specialists
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215507984
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,500.00 12/01/2025 Non-covered Recipient Entity
Southern California Heart Specialists
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215507987
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 12/01/2025 Non-covered Recipient Entity
Southern California Heart Specialists
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215507991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,150.96 11/25/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184264353
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,300.00 11/25/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184264357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.40 11/25/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184264359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $80.24 11/25/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184264361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,387.36 11/20/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184263341
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,598.00 11/19/2025 Non-covered Recipient Entity
Southern California Heart Specialists
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215507976
Principal investigator 1 Alnylam Pharmaceuticals Inc. $10,000.00 11/19/2025 Non-covered Recipient Entity
Southern California Heart Specialists
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215507980
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,561.84 11/14/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184260977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,600.00 11/13/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
Psychometric Evaluation of the Living with Postural Orthostatic Tachycardia Syndrome Questionnaire No dispute reported 06/30/2026 1184260705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 11/13/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
Psychometric Evaluation of the Living with Postural Orthostatic Tachycardia Syndrome Questionnaire No dispute reported 06/30/2026 1184260711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,962.80 11/07/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184257913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,100.00 11/07/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184257917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $80.24 11/07/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184257919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $46.00 11/07/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184257921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 11/07/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184257929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 11/07/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184257931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,561.44 10/29/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184253780
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,054.56 10/23/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184252822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,800.00 10/23/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184252828
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,979.52 10/16/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184250867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,203.36 10/09/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184249092
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,953.52 10/03/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184244845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184244847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $934.08 10/03/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184244861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,321.28 09/12/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184236704
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 09/12/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184236706
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23.00 09/12/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184236708
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,600.00 09/11/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
Psychometric Evaluation of the Living with Postural Orthostatic Tachycardia Syndrome Questionnaire No dispute reported 06/30/2026 1184235911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,027.28 09/04/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184235309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,782.40 08/26/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184230489
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $700.00 08/21/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184229805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 08/21/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184229807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $80.24 08/14/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184228425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.00 08/14/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184228427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.40 08/14/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184228429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,800.00 08/14/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
Psychometric Evaluation of the Living with Postural Orthostatic Tachycardia Syndrome Questionnaire No dispute reported 06/30/2026 1184228635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,482.96 08/07/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184226361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,262.64 07/22/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184217951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,573.44 07/17/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184217264
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,706.16 07/10/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184214528
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.12 07/10/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184214530
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 07/10/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184214532
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $92.48 07/10/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184214534
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,641.52 07/04/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184213039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 07/04/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184213041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $800.00 07/03/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
Psychometric Evaluation of the Living with Postural Orthostatic Tachycardia Syndrome Questionnaire No dispute reported 06/30/2026 1184212653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,759.84 06/24/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184210768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/24/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184210774
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $800.00 06/20/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
Psychometric Evaluation of the Living with Postural Orthostatic Tachycardia Syndrome Questionnaire No dispute reported 06/30/2026 1184209442
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,882.56 06/19/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184209302
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/19/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184209304
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,706.16 06/12/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184206539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.40 06/12/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184206547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $600.00 06/12/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184206549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $80.24 06/12/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184206551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,297.84 06/05/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184204137
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/05/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184204385
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/05/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184204387
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.40 06/05/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184204389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,387.20 06/05/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184204395
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $80.24 06/05/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184204397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,400.00 06/02/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
Psychometric Evaluation of the Living with Postural Orthostatic Tachycardia Syndrome Questionnaire No dispute reported 06/30/2026 1184200789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,641.52 05/22/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184197717
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/22/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184197719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $562.40 05/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184194871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $80.24 05/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184194873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 05/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184194875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.24 05/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184194885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 05/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184194887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.12 05/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184194889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.40 05/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184194891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 05/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184194893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $80.24 05/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184194895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 05/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184194897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,502.80 05/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184194899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $257.12 05/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184194901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $400.00 05/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184194905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,600.00 05/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
Psychometric Evaluation of the Living with Postural Orthostatic Tachycardia Syndrome Questionnaire No dispute reported 06/30/2026 1184196269
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,200.00 05/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
Psychometric Evaluation of the Living with Postural Orthostatic Tachycardia Syndrome Questionnaire No dispute reported 06/30/2026 1184196275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,214.96 04/28/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184190683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,268.00 04/23/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184189005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $800.00 04/17/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
Psychometric Evaluation of the Living with Postural Orthostatic Tachycardia Syndrome Questionnaire No dispute reported 06/30/2026 1184184774
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,502.80 04/15/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184183328
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $800.00 04/10/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
Psychometric Evaluation of the Living with Postural Orthostatic Tachycardia Syndrome Questionnaire No dispute reported 06/30/2026 1184182922
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,058.64 04/08/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184181978
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,980.80 04/01/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184180668
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,561.84 03/25/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184178782
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,400.00 03/19/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184174400
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $700.00 03/19/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184174402
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 03/14/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184173922
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 03/11/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184170750
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36,574.48 03/11/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184170752
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $80.24 03/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184157107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184157109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.40 03/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184157111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $92.48 03/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184157113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184157115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.12 03/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184157117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 03/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184157119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184157121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.40 03/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184157123
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $80.24 03/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184157125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.12 03/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184157127
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.40 03/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184157129
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,000.00 03/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184157131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,041.00 03/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184157133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,700.00 03/06/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184157135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,000.00 01/09/2025 Non-covered Recipient Entity
PROFOUND RESEARCH LLC
Psychometric Evaluation of the Living with Postural Orthostatic Tachycardia Syndrome Questionnaire No dispute reported 06/30/2026 1184147475